Pharmacy Technician Certification Exams — Pharmacy Technician Certification Exam Answers
Answer: C
The required dosage to be administered daily is 0.7 mL.
To administer 7000 units of heparin, which is supplied at a concentration of 10,000 units per mL, the calculation shows that 0.7 mL is necessary for the prescribed dosage.
A) 0.07
This option is incorrect because administering 0.07 mL would only provide 700 units of heparin, which is significantly less than the required 7000 units.
B) 0.14
This option is also incorrect, as 0.14 mL would result in 1400 units of heparin. This amount is still far below the required dosage of 7000 units.
C) 0.7
This option is correct because administering 0.7 mL will deliver exactly 7000 units of heparin. The calculation is straightforward: 7000 units divided by 10,000 units/mL equals 0.7 mL.
D) 1.42
This option is incorrect as 1.42 mL would provide 14200 units of heparin, exceeding the required dosage of 7000 units significantly.
Conclusion
The correct answer is 0.7 mL, as it accurately delivers the prescribed dose of heparin based on the supplied concentration. All other options fail to meet the required dosage, either falling short or exceeding the necessary amount. Thus, understanding the conversion and calculation for medication dosage is crucial in medical practice.
Answer: B
Patients with hypertension must use decongestant products containing pseudoephedrine with caution.
Pseudoephedrine can cause an increase in blood pressure due to its vasoconstrictive properties, making it particularly concerning for patients with hypertension. Therefore, individuals with this condition should be cautious when using products containing this medication.
A) asthma
While pseudoephedrine can have some effects on bronchial passages, it is not primarily contraindicated for asthma patients. Asthma management typically does not involve significant risk from pseudoephedrine, unlike patients with hypertension.
B) hypertension
Patients with hypertension are advised to use pseudoephedrine with caution because it can elevate blood pressure. This condition poses a direct risk when using decongestants that may exacerbate cardiovascular issues.
C) hypokalemia
Hypokalemia, or low potassium levels, is not directly affected by pseudoephedrine. While maintaining potassium levels is crucial in general health, this condition does not specifically warrant caution when using decongestants containing pseudoephedrine.
D) eczema
Eczema is a skin condition and has no significant interaction with pseudoephedrine. Patients with eczema do not need to exercise caution regarding this medication, as it does not impact the skin condition.
Conclusion
Caution is specifically warranted for patients with hypertension when using pseudoephedrine due to its potential to increase blood pressure. The other conditions listed do not present the same level of risk associated with the use of this medication. Thus, hypertension is the most relevant concern among the options provided.
Answer: D
The product's quality and efficacy is guaranteed until September 30, 2026.
A manufacturer expiration date of 09/26 indicates that the product is guaranteed to maintain its quality and efficacy until the last day of September 2026.
A) August 31, 2026.
This option is incorrect because it suggests that the product expires at the end of August, which does not align with the manufacturer expiration date of September 26, 2026. The product should be good through the entire month of September.
B) September 1, 2026.
This option is also incorrect as it implies that the product's efficacy ends on the first day of September. The expiration date indicates that the product is valid until the end of September, not just the beginning.
C) September 26, 2026.
While this option appears close, it is incorrect because it suggests the product's efficacy ends on the day of the expiration date. However, most expiration dates typically mean that the product is effective until the last day of the specified month.
D) September 30, 2026.
This option is correct because it accurately reflects that the product's quality and efficacy are guaranteed until the end of September 2026, which is the last day of the month following the expiration date.
Conclusion
The correct answer, September 30, 2026, clearly indicates the full duration of efficacy based on the manufacturer's expiration date. All other options fail to recognize that expiration dates generally allow for the product's use up until the end of the specified month. Therefore, it is crucial to understand that expiration dates are typically inclusive of the entire month indicated.
Answer: B
Two errors are present in the label for guaifenesin DM.
The label incorrectly states the dosage frequency and the amount per dose. It should indicate taking the medication four times a day (q.i.d.) instead of two times a day, and it also misrepresents the volume of medication to be taken, stating 10 mL instead of the correct 5 mL (1 tsp).
A) 1
This option is incorrect because there are two clear errors in the label. The frequency and the dosage amount both do not match the prescription, thus making this option insufficient to describe the inaccuracies.
B) 2
This option is correct as it identifies both errors present in the label. The frequency of administration is incorrect, and the amount to be taken is also wrong. Both issues must be recognized to understand the total number of errors accurately.
C) 3
This option is incorrect because it overstates the number of errors. There are only two distinct errors in the label regarding frequency and dosage, so claiming three errors does not align with the information provided.
D) 4
This option is also incorrect as it exaggerates the number of errors. There are only two critical mistakes identified in the prescription label, making four errors an inaccurate assessment of the situation.
Conclusion
In summary, the correct answer is two errors, as the label incorrectly specifies the administration frequency and the dosage amount. All other options fail to accurately represent the errors found in the label, either underestimating or overestimating the number of mistakes. Understanding the precise requirements of medication labeling is crucial for patient safety and adherence to the prescription.
5. Rivastigmine has the same mechanism of action as:
Answer: C
Rivastigmine has the same mechanism of action as Donepezil.
Rivastigmine and Donepezil both act as acetylcholinesterase inhibitors, which are used to increase the levels of acetylcholine in the brain, thereby enhancing cognitive function in conditions like Alzheimer's disease.
A) Dorzolamide
Dorzolamide is a carbonic anhydrase inhibitor primarily used to lower intraocular pressure in conditions like glaucoma. It does not share the same mechanism of action as Rivastigmine, which targets acetylcholinesterase.
B) Doxazosin
Doxazosin is an alpha-1 adrenergic antagonist, mainly used to treat hypertension and benign prostatic hyperplasia. Its mechanism of action is unrelated to that of Rivastigmine, which focuses on neurotransmitter modulation in the brain.
C) Donepezil
Donepezil is an acetylcholinesterase inhibitor, just like Rivastigmine. Both medications work by preventing the breakdown of acetylcholine, thereby improving cholinergic transmission and cognitive function in patients with Alzheimer's disease.
D) Doxycycline
Doxycycline is a tetracycline antibiotic used to treat various bacterial infections. It does not share any mechanism of action with Rivastigmine, which is focused on enhancing cholinergic activity in the brain.
Conclusion
Rivastigmine and Donepezil both function as acetylcholinesterase inhibitors, making Donepezil the correct answer. The other options, Dorzolamide, Doxazosin, and Doxycycline, operate through entirely different mechanisms and are used for different medical conditions, thus confirming their incorrectness in relation to the question.
Answer: B
A pharmacy technician must provide a patient package insert for estrogen products.
Patients receiving estrogen products are required to be given a patient package insert, which contains important information about the medication, including its uses, risks, and benefits.
A) Antibiotics
While antibiotics are important medications, they typically do not require a patient package insert to be provided to patients. Instead, information regarding dosage and potential side effects is usually provided verbally or through standard pharmacy instructions.
B) Estrogen products
Estrogen products are classified as hormonal medications that require a patient package insert. This insert is crucial as it provides detailed information about the risks associated with hormone therapy, including potential side effects and contraindications, ensuring that patients are well-informed.
C) Infused chemotherapy
Infused chemotherapy medications often come with specific guidelines and information, but they do not typically require a patient package insert in the same manner that estrogen products do. Instead, patient education usually occurs through healthcare providers during the treatment process.
D) Antidiabetics
Antidiabetic medications may come with informational materials, but a formal patient package insert is not required for all antidiabetic drugs. Patients are often educated about their medication through consultations with healthcare professionals rather than through standardized inserts.
Conclusion
The necessity of providing a patient package insert is specifically mandated for estrogen products, making option B the correct choice. Other medications listed do not have the same requirement, emphasizing the importance of informed consent and understanding the implications of hormone therapy for patients.
Answer: C
The prescription label for a controlled substance must contain the name of the patient and the name of the prescriber.
In accordance with federal law, a prescription label for a controlled substance dispensed by a pharmacist must include the name of the patient and the name of the prescriber to ensure proper identification and accountability.
A) name and address of the prescriber
While the name of the prescriber is required on the prescription label, the address is not a mandatory element specified by federal law. Therefore, this option is incomplete and does not fulfill the requirement set forth for controlled substances.
B) pharmacy and prescriber's DEA registration numbers
Though the pharmacy's DEA registration number is pertinent for controlled substances, it is not required on the prescription label itself. The prescriber’s DEA number is also not mandated to be displayed on the label, making this option incorrect.
C) name of the patient and the name of the prescriber
This option correctly outlines the mandatory information that must be present on the prescription label for a controlled substance. Including both the patient's name and the prescriber's name is essential for proper identification and ensures compliance with federal regulations.
D) name and age of the patient
While the name of the patient is necessary, the age of the patient is not a required piece of information on the prescription label according to federal law. This makes this option incomplete and therefore incorrect.
Conclusion
The correct answer, which includes both the name of the patient and the name of the prescriber, aligns with federal law requirements for prescription labeling of controlled substances. Other options either lack required information or include unnecessary details, highlighting the importance of specific compliance in pharmaceutical practices.
Answer: C
Ciprofloxacin oral suspension remains stable for a maximum of 14 days when stored in a refrigerator.
Ciprofloxacin oral suspension, once reconstituted, is stable for a maximum of 14 days when kept in a refrigerator.
A) 3
Option A is incorrect because ciprofloxacin oral suspension can be stored for longer than 3 days. The short shelf life of 3 days does not align with the stability information provided for this medication.
B) 7
Option B is also incorrect. While ciprofloxacin may be stable for a week, the actual maximum stability period extends beyond 7 days, making this option insufficient.
C) 14
Option C is correct as ciprofloxacin oral suspension, after reconstitution, is stable for up to 14 days when stored in the refrigerator. This aligns with the recommended guidelines for its storage.
D) 28
Option D is incorrect because ciprofloxacin oral suspension does not remain stable for 28 days post-reconstitution. This period exceeds the established stability timeframe for the medication.
Conclusion
Ciprofloxacin oral suspension is stable for a maximum of 14 days in the refrigerator, making option C the definitive correct answer. Options A, B, and D are incorrect as they either underestimate or overstate the stability duration, failing to reflect the actual stability guidelines for this medication.
Answer: D
Potassium chloride IV concentrate is considered a high-alert/high-risk medication.
Potassium chloride IV concentrate is classified as a high-alert medication due to its potential to cause significant harm if misused or administered incorrectly. This status is assigned by the Institute for Safe Medication Practices (ISMP) based on the serious health risks associated with its use.
A) Acetaminophen extra strength caplets
Acetaminophen extra strength caplets are generally considered safe when used at recommended doses and are not classified as high-alert medications. While overdose can lead to serious liver damage, it does not carry the same level of risk in clinical settings as high-alert medications.
B) Furosemide oral tablets
Furosemide oral tablets are commonly used diuretics and, while they require careful monitoring due to potential electrolyte imbalances, they are not categorized as high-alert medications. The risks associated with furosemide are significant but do not elevate it to the same risk level as high-alert medications.
C) Ceftriaxone sodium for injection
Ceftriaxone sodium for injection is a broad-spectrum antibiotic and, although it requires cautious administration due to potential adverse effects and interactions, it is not classified as a high-alert medication. The risk factors associated with its use do not meet the criteria set by ISMP for high-alert status.
D) Potassium chloride IV concentrate
Potassium chloride IV concentrate is designated as a high-alert medication because improper dosing or administration can lead to severe hyperkalemia, cardiac arrest, or death. The high risk of serious adverse effects makes it imperative that this medication is handled with extra caution.
Conclusion
Potassium chloride IV concentrate is definitively identified as a high-alert medication due to the grave consequences of its misuse. In contrast, the other medications listed, while they may pose risks, do not fulfill the criteria established by ISMP for high-alert status. This distinction underscores the importance of vigilance in the handling and administration of high-risk medications to ensure patient safety.
10. Patients should avoid grapefruit juice while taking:
Answer: A
Patients should avoid grapefruit juice while taking Simvastatin.
Grapefruit juice is known to interact with certain medications, particularly those metabolized by the liver. Simvastatin is one such medication, as grapefruit juice can increase its concentration in the bloodstream, leading to a higher risk of side effects.
A) Simvastatin
This option is correct because grapefruit juice inhibits the CYP3A4 enzyme, which is responsible for metabolizing simvastatin. Consequently, consuming grapefruit juice can significantly increase the levels of simvastatin in the body, heightening the risk of adverse effects such as muscle damage.
B) Ibuprofen
This option is incorrect. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that does not have a known interaction with grapefruit juice. Therefore, patients taking ibuprofen do not need to avoid grapefruit juice.
C) Lisinopril
This option is also incorrect. Lisinopril is an ACE inhibitor used to treat high blood pressure and heart failure, and it does not interact with grapefruit juice. Patients can safely consume grapefruit while on lisinopril.
D) Doxycycline
This option is incorrect as well. Doxycycline is an antibiotic that does not have a significant interaction with grapefruit juice. Patients taking doxycycline are not required to avoid grapefruit juice.
Conclusion
Simvastatin is uniquely affected by grapefruit juice due to its metabolism by the CYP3A4 enzyme, which can lead to increased drug levels and potential side effects. In contrast, ibuprofen, lisinopril, and doxycycline do not exhibit such interactions, making them safe to use with grapefruit juice. Thus, avoiding grapefruit juice is essential only when taking simvastatin.